Keyword search

Filter results by

Search Help
Currently selected filters that can be removed

Keyword(s)

Type

1 facets displayed. 0 facets selected.

Year of publication

7 facets displayed. 0 facets selected.

Geography

2 facets displayed. 0 facets selected.

Survey or statistical program

1 facets displayed. 1 facets selected.
Sort Help
entries

Results

All (14)

All (14) (0 to 10 of 14 results)

  • Articles and reports: 88-003-X200700210323
    Geography: Canada
    Description:

    Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210325
    Geography: Canada
    Description:

    Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10

  • Articles and reports: 88F0006X2005010
    Description:

    This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.

    Release date: 2005-04-29

  • Articles and reports: 88-003-X20050017771
    Geography: Canada
    Description:

    Preliminary data indicate the biotechnology sector continued its phenomenal growth in Canada between 2001 and 2003, generating almost $4 billion in revenues. Biotechnology companies have more than quadrupled their revenues since 1997, making biotech a quickly growing activity.

    Release date: 2005-02-09

  • Articles and reports: 88F0006X2004017
    Description:

    Using data from the 1997 Biotechnology Firm Survey and the 1999 and 2001 cycles of the Biotechnology Use and Development Survey, this article portrays the evolution of key indicators of Canadian biotechnology companies from 1997 to 2001.

    Release date: 2004-10-22

  • Articles and reports: 88F0006X2003005
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2001 Biotechnology Use and Development Survey. Within the last few years, except for the amount of financing capital raised, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 358 in 1999 to 375 in 2001. The Human Health sector outpaces all the other sectors in terms of the number of firms, human resources, biotechnology revenues, biotechnology research and development expenditures, amount of financing capital raised, and the number of products in the pipeline. Contrary to medium-sized and large firms where the personnel is more homogenous, small firms employ mostly highly-qualified workers. The 2001 data show a maturing trend in small firms. Most firms could not hire enough people to fill all their vacancies (estimated at 953 positions in Canada) for the 2001 year.

    Release date: 2003-03-28

  • Articles and reports: 88F0006X2003003
    Description:

    Results show that biotechnology companies in Canada are experiencing rapid growth and that Statistics Canada is now capturing more biotechnology activity. For example, between 1997 and 1999, Canadian biotechnology firms grew in number with core biotechnology firms increasing from 282 firms to 358. They brought in $1.9 billion in biotechnology revenues in 1999, compared with $813 million in 1997; they spent around $827 million on biotechnology research and development in 1999, compared with $494 million in 1997.

    Release date: 2003-03-10

  • Articles and reports: 88-003-X20030016474
    Geography: Canada, Province or territory
    Description:

    In 2001, there were 375 biotechnology innovator firms in Canada, an increase of just under 5% from the 358 firms in 1999. Analysis beyond these overall statistics discloses a dynamic churning that is occurring among sectors, provinces and size groups.

    Release date: 2003-02-18

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25
Data (0)

Data (0) (0 results)

No content available at this time.

Analysis (14)

Analysis (14) (0 to 10 of 14 results)

  • Articles and reports: 88-003-X200700210323
    Geography: Canada
    Description:

    Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210325
    Geography: Canada
    Description:

    Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10

  • Articles and reports: 88F0006X2005010
    Description:

    This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.

    Release date: 2005-04-29

  • Articles and reports: 88-003-X20050017771
    Geography: Canada
    Description:

    Preliminary data indicate the biotechnology sector continued its phenomenal growth in Canada between 2001 and 2003, generating almost $4 billion in revenues. Biotechnology companies have more than quadrupled their revenues since 1997, making biotech a quickly growing activity.

    Release date: 2005-02-09

  • Articles and reports: 88F0006X2004017
    Description:

    Using data from the 1997 Biotechnology Firm Survey and the 1999 and 2001 cycles of the Biotechnology Use and Development Survey, this article portrays the evolution of key indicators of Canadian biotechnology companies from 1997 to 2001.

    Release date: 2004-10-22

  • Articles and reports: 88F0006X2003005
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2001 Biotechnology Use and Development Survey. Within the last few years, except for the amount of financing capital raised, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 358 in 1999 to 375 in 2001. The Human Health sector outpaces all the other sectors in terms of the number of firms, human resources, biotechnology revenues, biotechnology research and development expenditures, amount of financing capital raised, and the number of products in the pipeline. Contrary to medium-sized and large firms where the personnel is more homogenous, small firms employ mostly highly-qualified workers. The 2001 data show a maturing trend in small firms. Most firms could not hire enough people to fill all their vacancies (estimated at 953 positions in Canada) for the 2001 year.

    Release date: 2003-03-28

  • Articles and reports: 88F0006X2003003
    Description:

    Results show that biotechnology companies in Canada are experiencing rapid growth and that Statistics Canada is now capturing more biotechnology activity. For example, between 1997 and 1999, Canadian biotechnology firms grew in number with core biotechnology firms increasing from 282 firms to 358. They brought in $1.9 billion in biotechnology revenues in 1999, compared with $813 million in 1997; they spent around $827 million on biotechnology research and development in 1999, compared with $494 million in 1997.

    Release date: 2003-03-10

  • Articles and reports: 88-003-X20030016474
    Geography: Canada, Province or territory
    Description:

    In 2001, there were 375 biotechnology innovator firms in Canada, an increase of just under 5% from the 358 firms in 1999. Analysis beyond these overall statistics discloses a dynamic churning that is occurring among sectors, provinces and size groups.

    Release date: 2003-02-18

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25
Reference (0)

Reference (0) (0 results)

No content available at this time.

Date modified: